Actinium Pharmaceuticals Inc (ATNM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Actinium Pharmaceuticals Inc (ATNM) has a cash flow conversion efficiency ratio of -2.548x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.87 Million) by net assets ($2.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Actinium Pharmaceuticals Inc (ATNM) market capitalisation for the company's overall valuation and market capitalisation.
Actinium Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Actinium Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Actinium Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Actinium Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Actinium Pharmaceuticals Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Turism Hotelur
RO:EFO
|
N/A |
|
Mind Technology Inc
NASDAQ:MIND
|
0.022x |
|
Brand 24 SA
WAR:B24
|
0.338x |
|
Rockhaven Resources Ltd
V:RK
|
-0.001x |
|
GROUP PAREF INH. EO 25
F:G5I
|
N/A |
|
Gold Strike Resources Corp.
V:GSR
|
-0.169x |
|
ERREDUE S.P.A.
F:Z9H
|
N/A |
|
Tower Real Estate Investment Trust
KLSE:5111
|
0.025x |
Annual Cash Flow Conversion Efficiency for Actinium Pharmaceuticals Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of Actinium Pharmaceuticals Inc from 2006 to 2025. View ATNM live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.83 Million | $-24.58 Million | -3.138x | -210.78% |
| 2024-12-31 | $32.76 Million | $-33.07 Million | -1.010x | +22.41% |
| 2023-12-31 | $36.38 Million | $-47.34 Million | -1.301x | -1100.72% |
| 2022-12-31 | $66.48 Million | $8.64 Million | 0.130x | +145.83% |
| 2021-12-31 | $73.55 Million | $-20.87 Million | -0.284x | +19.52% |
| 2020-12-31 | $61.32 Million | $-21.62 Million | -0.353x | +90.73% |
| 2019-12-31 | $5.64 Million | $-21.46 Million | -3.802x | -62.89% |
| 2018-12-31 | $8.81 Million | $-20.57 Million | -2.334x | -48.06% |
| 2017-12-31 | $13.67 Million | $-21.55 Million | -1.577x | -36.57% |
| 2016-12-31 | $18.01 Million | $-20.79 Million | -1.154x | -36.80% |
| 2015-12-31 | $21.97 Million | $-18.54 Million | -0.844x | -111.31% |
| 2014-12-31 | $-1.92 Million | $-14.35 Million | 7.463x | +84.98% |
| 2013-12-31 | $-1.56 Million | $-6.29 Million | 4.035x | +188.68% |
| 2012-12-31 | $1.15 Million | $-5.21 Million | -4.550x | -71087.78% |
| 2011-12-31 | $-84.33K | $539.00 | -0.006x | +92.28% |
| 2010-12-31 | $-94.62K | $7.83K | -0.083x | -142.45% |
| 2009-12-31 | $-96.29K | $-18.78K | 0.195x | +3.32% |
| 2008-12-31 | $-73.96K | $-13.96K | 0.189x | -59.53% |
| 2007-12-31 | $-33.20K | $-15.49K | 0.467x | -38.81% |
| 2006-12-31 | $-18.40K | $-14.03K | 0.763x | -- |
About Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular… Read more